Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to improve glycaemic control, reduce body weight, and reduce the risk of major adverse CV events, in people with atherosclerotic CV disease and T2D. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.